Asset Details
Do you wish to reserve the book?
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
Do you wish to request the book?
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
2011
Overview
Background:
Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC).
Methods:
In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability.
Results:
After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (
P
=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks
vs
31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand–foot syndrome, hypertension, and diarrhoea. Grade 3–4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively.
Conclusion:
The combination of sorafenib and IL-2 did not demonstrate improved efficacy
vs
sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Benzenesulfonates - administration & dosage
/ Benzenesulfonates - adverse effects
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - pathology
/ Female
/ Humans
/ Interleukin-2 - administration & dosage
/ Interleukin-2 - adverse effects
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - pathology
/ Kidneys
/ Male
/ Nephrology. Urinary tract diseases
/ Niacinamide - analogs & derivatives
/ Oncology
/ Pyridines - administration & dosage
/ Tumors
